Background: Vaborbactam is a novel inhibitor of serine b-lactamases, including KPCs, which predominate in China. It is being developed in combination with meropenem.
Introduction
Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) have emerged worldwide, posing a global public health threat and a formidable challenge to antimicrobial therapy. Possible carbapenem resistance mechanisms include carbapenemase production, loss or alteration of porins and increased efflux system activity. 1 Enterobacteriaceae that produce KPCs are the leading cause of carbapenem-resistant infections in China and other regions including the USA, Italy and Greece, creating an urgent public health threat that requires immediate action. [2] [3] [4] [5] Carbapenemase-producing Enterobacteriaceae (CPE) are resistant to nearly all b-lactam agents, limiting therapeutic options available for the treatment of CPE infections. 6 Historically, the use of b-lactamase inhibitors (clavulanate, sulbactam and tazobactam) combined with a potent b-lactam has been successful in combating b-lactamase-mediated resistance. However, these compounds are generally not effective against carbapenemases, including KPC and metalloenzymes. 7 Thus, new b-lactamase inhibitors are urgently needed to control the spread of CRE.
Vaborbactam (formerly RPX7009) is a new cyclic boronic acid b-lactamase inhibitor that displays potent inhibition of KPC enzymes and other Ambler class A and C enzymes. 8 It is being developed in combination with the carbapenem meropenem. As part of the drug development programme, two Phase 3 clinical trials were completed in patients with complicated urinary tract infections 9 and patients with serious infections known or suspected to be caused by CRE. 10 Vaborbactam in combination with Several studies have shown that vaborbactam enhances the in vitro activity of meropenem against KPC-producing Enterobacteriaceae. 6, [12] [13] [14] [15] Based on these reports, 96%-99% of isolates were inhibited at 4 mg/L meropenem with vaborbactam at 8 mg/L. While these studies were carried out on isolates collected worldwide, they included a very limited number of isolates from China. Thus, there are limited data on the combined activity of meropenem/vaborbactam against KPC-producing Enterobacteriaceae strains from China.
In this study, we evaluated the in vitro activities of meropenem/ vaborbactam and 11 comparator antimicrobial agents against 128 KPC-producing Enterobacteriaceae isolates collected from 16 hospitals in China (2004-14) .
Materials and methods

Bacterial isolates
The study was conducted at Peking Union Medical College Hospital (PUMCH), Beijing, China. A total of 128 prospectively collected, non-duplicated, KPC-producing Enterobacteriaceae isolates from blood (n " 41), midstream urine (n " 30), pus (n " 17), abdominal fluid (n " 10), drainage fluid (n " 8), bile (n " 6), sputum (n " 6) and various sterile and non-sterile sites (n " 10) from 16 teaching hospitals located in 12 provinces in China were studied (Table S1 , available as Supplementary data at JAC Online). The identity of the isolates was confirmed by MALDI-TOF MS (Bruker Biotyper) at PUMCH.
Antimicrobial susceptibility testing
MICs were determined using the CLSI broth microdilution method (BMD), 16 with panels prepared in-house. BMD panels included the following antimicrobial agents: polymyxin B [concentration range (CR) " 0.06-64 mg/L], tigecycline (CR " 0.06-64 mg/L) and ertapenem, cefoperazone/sulbactam, piperacillin/tazobactam, ceftazidime, ceftriaxone, cefepime, cefoxitin, amikacin and levofloxacin (each with CR " 0.06-256 mg/L). Meropenem (CR " 0.06-64 mg/L) and vaborbactam (CR " 0.5-32 mg/L) were tested in a chequerboard configuration using CAMHB. 17 All data were imported into WHONET 5.6 software and interpreted according to CLSI 2017 breakpoints at PUMCH. 18 Vaborbactam was provided by Rempex (San Diego, CA, USA) and all other antimicrobial agents were purchased from the National Institute for Food and Drug Control. Quality control (QC) was performed using Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853 and Klebsiella pneumoniae ATCC BAA-1705. All QC results were within acceptable ranges as published in CLSI documents. 19 
Gene sequencing analysis
All the isolates were screened for carbapenemases using the modified Hodge test (MHT) and modified carbapenem inactivation method (mCIM). 18, 20 After this, multiplex PCR, followed by DNA sequencing of a variety of b-lactamase-encoding genes, including those encoding Ambler class A (bla KPC , bla NMC , bla SME , bla IMI , bla GES , bla PER , bla VEB , bla TEM , bla SHV and bla CTX-M ), class B (bla IMP , bla VIM , bla NDM , bla SPM , bla SIM and bla GIM ), class C (bla AMPC and bla CMY ) and class D (bla OXA ) enzymes, were performed for specific b-lactamase gene confirmation. 21 All the K. pneumoniae and E. coli isolates were further characterized by MLST (http://bigsdb.pasteur.fr/ klebsiella/klebsiella.html and http://mlst.warwick.ac.uk/mlst/dbs/Ecoli). Based on antimicrobial susceptibility testing results, 14 K. pneumoniae isolates were randomly selected for further analysis. The meropenem MICs for these isolates (in the presence of 8 mg/L vaborbactam) ranged from 0.06 to .64 mg/L (MIC 0.06 mg/L, four isolates; MIC " 1 mg/L, one isolate; MIC " 2 mg/L, one isolate; MIC " 4 mg/L, two isolates; MIC " 8 mg/L, five isolates; and MIC .64 mg/L, one isolate). bla KPC and the porin genes ompK35 and ompK36 were amplified and sequenced as previously described. 22 The obtained gene sequences were compared with those in the database located at the NCBI blast server (http://blast.ncbi.nlm.nih.gov).
Gene expression analysis
The expression of bla KPC-2 , the AcrAB-TolC efflux pump gene (acrB) and outer membrane protein genes (ompK35 and ompK36) was determined by quantitative real-time PCR for the 14 randomly selected K. pneumoniae isolates. Total RNA was extracted using the RNeasy Mini Kit (QIAGEN, Hilden, Germany) and was treated with RNase-free DNase (Invitrogen, Paisley, UK). Relative quantification of target genes was then performed in triplicate by normalization to an endogenous reference gene (rpoB) on an ABI ViiA TM sequencing instrument (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions, using previously described primers. 23, 24 Transcription levels of bla KPC-2 were compared with that in K. pneumoniae ATCC BAA-1705, while those for the efflux pump and outer membrane proteins were compared with those in K. pneumoniae ATCC 13883. Transcription levels were considered significantly different if a 10-fold difference (higher for acrB and lower for the outer membrane protein genes), compared with the level for the control isolates, was noted. 
Cumulative MIC distributions of meropenem/ vaborbactam stratified by different bacterial species
Cumulative MIC distributions of meropenem/vaborbactam stratified by different species are shown in Table 2 . Meropenem alone displayed very limited activity against K. pneumoniae (MIC 50 and MIC 90 , .64 mg/L), E. coli (MIC 50 and MIC 90 , 16 and .64 mg/L, respectively) and other species (including five E. cloacae, three E. aerogenes, two S. marcescens, one K. oxytoca and one P. mirabilis; MIC 50 and MIC 90 , 32 and .64 mg/L, respectively). When tested in combination with vaborbactam, strong dose-response synergy was evident irrespective of species. In the case of K. pneumoniae, 53.2%, 76.6%, 96.8% and 100% of isolates were inhibited by 4 mg/L meropenem with 4, 8, 16 and 32 mg/L vaborbactam, respectively. MIC 50 and MIC 90 of MV 8 were 1 and 8 mg/L, respectively. KPC-producing isolates of E. coli appeared to be more susceptible to the meropenem/vaborbactam combination, with 100% of isolates inhibited by 4 mg/L meropenem in the presence of 
Evaluation of intrinsic mechanisms of resistance to meropenem/vaborbactam
Fourteen K. pneumoniae isolates with a wide range of MV 8 MICs were selected to investigate the impact of known meropenem resistance mechanisms (decreased uptake due to mutations or decreased expression of porin genes; increased expression of bla KPC or AcrAB efflux pump gene) on MV 8 susceptibility (Table 5) . Five isolates (including the KPC-producing ATCC BAA-1705 QC control strain) had a meropenem-alone MIC ranging from 8 to 32 mg/L and an MV 8 MIC 0.06 mg/L. These isolates had fulllength ompK36 and either full-length or truncated ompK35 (BAA-1705), which was presumed to be non-functional. Some differences in the transcription levels of bla KPC-2 and acrB were observed. Two strains, R37 and Y18, had 20-and 10-fold lower expression of ompK35, compared with ATCC 13883. Y18 also had reduced expression of acrB. Slightly increased expression of bla KPC-2 was found in strain R37 and H104 compared with other isolates from this group.
The remaining 10 isolates had a meropenem-alone MIC of .64 mg/L and an MV 8 MIC ranging from 1 to .64 mg/L. All of these isolates had mutations in both porin genes. The most frequent mutation in the ompK35 gene (carried by 9/10 isolates) was a deletion of A at nucleotide 86 that caused a frameshift from amino acid 29 (FS_aa29) resulting in a truncated, non-functional protein. 25 One isolate (Y70) had a 2.5 kb insertion in ompK35, inactivating this gene. Of note, transcriptional levels of mutated ompK35 mRNAs were reduced nearly 100-fold. The most frequent mutation in the ompK36 gene (8/10 isolates) was a duplication of two amino acids, glycine (G) and aspartic acid (D), at positions 136 and 137 (GD duplication). As was hypothesized in earlier studies, GD duplication creates a defective (but still partially functional) porin that has a narrowed channel and, consequently, decreased rate of uptake of compounds that cross the outer membrane through OmpK36. 25 One strain, L159, did not produce an ompK36 PCR product and had no expression of ompK36 mRNA. The remaining strain, L080, had a truncated non-functional OmpK36 due to a stop codon (TAG) at amino acid 94.
We next compared strains with MV 8 MIC ranging from 1 to 4 mg/L (susceptible to meropenem/vaborbactam based on the FDA-approved breakpoint) versus strains with MV 8 MIC 8 mg/L. Four strains from the first group (L144, L152, H023 and L123) and four of the strains from the second group with MV 8 MIC of 8 mg/L (D35, D54, L145 and Y70) had the same or similar mutations in ompK35 (inactivation due to FS_aa29 or insertional inactivation) and ompK36 (GD duplication). Nevertheless, significantly different transcription levels were observed in the latter group with reduced expression of ompK36 in L145 and Y70 and increased expression of bla KPC-2 in D35 and D54, neither of which was seen in the former group. Interestingly, D54 also had .8) 0 (93.8) 0 (93.8) 1 (100) 0 (100) Meropenem/vaborbactam against Enterobacteriaceae JAC a high level of expression of both acrB (expected to cause an increase in MIC) and ompK36 (expected to cause a decrease in MIC). L159, another isolate with MV 8 MIC of 8 mg/L, did not produce a functional OmpK35 (FS_aa29) and did not have a detectable level of ompK36 either, supplemented with a slightly increased expression of bla KPC-2 . Finally, L080, the strain with the highest MV 8 MIC of .64 mg/L, had a combination of all of the studied resistance mechanisms: inactivation of both ompK35 (FS_aa29) and ompK36 (due to stop codon), significantly increased expression of bla KPC-2 and slightly increased expression of the gene acrB.
Discussion
This study evaluated the in vitro activities of meropenem, combined with various fixed concentrations of vaborbactam, and 11 comparator antimicrobial agents against 128 wellcharacterized KPC-producing Enterobacteriaceae isolates. MV 8 (the combination approved for in vitro susceptibility testing by the FDA) exhibited superior activity compared with other antimicrobial agents, with lower MIC 50 and MIC 90 (0.5 and 8 mg/L, respectively), except for polymyxin B (0.5 and 0.5 mg/L, respectively) and tigecycline (1 and 4 mg/L, respectively). Relative expression compared with control (set to 1).
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Comparison of the in vitro activities of meropenem alone and meropenem/vaborbactam yielded three key findings. First, vaborbactam strongly potentiated meropenem against KPC-positive Enterobacteriaceae in a dose-dependent manner, which is consistent with previous studies. 6, [12] [13] [14] [15] Higher vaborbactam concentrations (in the combination) resulted in a greater inhibition effect on the isolates than meropenem alone (Table 1) . Similarly to results reported by Hackel et al., 12 no appreciable differences in the activity of meropenem/vaborbactam against isolates which coproduced NSBLs, ESBLs or class C plasmidic b-lactamases with KPC were seen in our study. The apparent decrease in MIC 50 for isolates coproducing class C b-lactamases could be explained by the fact that there was a lower proportion of K. pneumoniae ST11 among such strains (Table S1) .
Second, it is noteworthy that there was a higher percentage of Enterobacteriaceae isolates in China for which MV 8 MIC was elevated compared with other geographical areas, such as Europe, North America and Latin America: MIC 90 of 8 mg/L for isolates from China versus 0.5-1 mg/L for the worldwide isolates. 6, [12] [13] [14] [15] 25 This reduced susceptibility was mainly driven by K. pneumoniae isolates; E. coli from China appeared to be as susceptible to meropenem/vaborbactam as those collected worldwide. In the case of K. pneumoniae, only 76.6% of isolates collected in China were inhibited by 4 mg/L MV 8 (the FDA-approved MIC breakpoint for susceptibility to meropenem/vaborbactam), while 96%-99% of worldwide isolates were inhibited at this concentration. On a positive note, animal and in vitro infection models using simulated human plasma pharmacokinetics for meropenem/ vaborbactam demonstrated antibacterial effects against KPC-producing strains of Enterobacteriaceae with MICs as high as 8-16 mg/L. [25] [26] [27] Based on vaborbactam exposure data from clinical trial patients, PTA was .90% at a meropenem/vaborbactam MIC of 8 mg/L, suggesting a PK/PD susceptibility breakpoint of 8/8 mg/L. 25, 28 If additional studies validate this provisional breakpoint, 97.7% and 96.8% of KPC-producing Enterobacteriaceae and K. pneumoniae from Chinese hospitals, respectively, will be considered susceptible to meropenem/vaborbactam. Nevertheless, the fact that a higher proportion of KPCproducing K. pneumoniae with a higher MV 8 MIC exist in China compared with other geographical areas remains. We hypothesize that a recently reported clonal dissemination of ST11 isolates might have contributed to the increased meropenem/vaborbactam MIC across Chinese hospitals. 25, 29, 30 In agreement with these reports, our study that involved testing of isolates collected from 16 different hospitals located in 12 provinces of China over a duration of 10 years found that 77.7% of K. pneumoniae isolates belonged to ST11. Based on our results, a high proportion of ST11 isolates had increased MV 8 MICs and a decreased susceptibility rate to meropenem/vaborbactam according to the FDA breakpoints compared with isolates belonging to other STs.
Third, despite the small number of isolates characterized, a close examination of 14 randomly selected K. pneumoniae isolates with a wide range of MV 8 MICs (0.06 to .64 mg/L) revealed a possible interplay between the functional status of major porins OmpK35 and OmpK36, and expression of bla KPC and acrB as factors that could possibly affect MV 8 MIC. Of note, all isolates with MV 8 MIC 1 mg/L belonged to ST11 except for Y70 (ST23). As shown in Table 5 , as long as an isolate had a functional OmpK36 porin, MV 8 MIC was 0.06 mg/L; it was not affected by the diminished OmpK35 (due to truncation of the protein or decreased expression of the gene) or an increased expression of either bla KPC or acrB alone.
However, MV 8 MIC was elevated (1 to .64 mg/L) in 10 isolates that carried various defects in both OmpK35 and OmpK36. This is consistent with a recent study employing a panel of isogenic KPCproducing strains of K. pneumoniae with various combinations of porin and efflux mutations and demonstrated an increase in MV 8 MIC against double-porin mutants. 23 Eight out of 10 isolates had a non-functional OmpK35 and a partially functional OmpK36, due to GD duplication, that presumably resulted in a reduced rate of uptake through the channel. 25 Still, these strains had a pretty wide distribution of MV 8 MIC that ranged from 1 to 8 mg/L. Among four strains with MV 8 MIC of 8 mg/L, D35 and D54 had a significantly higher expression of bla KPC while L145 and Y70 had a significantly lower expression of ompK36 compared with strains with MV 8 MIC 4 mg/L. Hence, reduced expression of a partially functional OmpK36 as well as overexpression of bla KPC on the background of double-porin gene mutations can apparently further increase MV 8 MIC.
The effect of a combination of multiple resistance mechanisms in a single cell on MV 8 MIC can be further illustrated by comparing L080 and L159. L080, the strain with the highest MV 8 MIC (.64 mg/L) contained loss-of-function mutations in both porin genes, had significantly overexpressed bla KPC and overexpressed acrB. L159, with an MV 8 MIC of 8 mg/L, similar to L080, also had both porins completely inactivated. However, in contrast to L080, it had lower levels of expression of both bla KPC and acrB, potentially implicating both factors in modulating MV 8 .
In conclusion, our findings suggest that meropenem/vaborbactam has good activity against KPC-producing Enterobacteriaceae from China. However, a higher percentage of K. pneumoniae isolates for which MV 8 MIC was elevated compared with other geographical areas is concerning. This might be due to clonal dissemination of ST11 KPC-producing isolates that are defective in both major porins, OmpK35 and OmpK36. While the majority of ST11 isolates carry a non-functional OmpK35 and a defective but still partially functional OmpK36, some strains have OmpK36 that is completely inactivated due to non-sense mutations in the corresponding gene. Complete inactivation of both porins in combination with an increased expression of both bla KPC and acrB might be associated with the highest observed MV 8 MIC. It remains to be determined whether additional factors might contribute to the increased MIC of meropenem/vaborbactam. 
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